ログイン
言語:

WEKO3

  • トップ
  • ランキング
To
lat lon distance
To

Field does not validate



インデックスリンク

インデックスツリー

メールアドレスを入力してください。

WEKO

One fine body…

WEKO

One fine body…

アイテム

{"_buckets": {"deposit": "0b5f3b9c-2084-4bfd-b848-7c6238224d06"}, "_deposit": {"id": "19155", "owners": [], "pid": {"revision_id": 0, "type": "depid", "value": "19155"}, "status": "published"}, "_oai": {"id": "oai:nagoya.repo.nii.ac.jp:00019155", "sets": ["1674"]}, "item_9_biblio_info_6": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2015-02", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "1-2", "bibliographicPageEnd": "93", "bibliographicPageStart": "81", "bibliographicVolumeNumber": "77", "bibliographic_titles": [{"bibliographic_title": "Nagoya Journal of Medical Science"}]}]}, "item_9_description_4": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "Celecoxib is a nonsteroidal anti-inflammatory drug (selective cyclooxygenase-2 inhibitor) that is widely used. The efficacy and safety of celecoxib for treatment of acute postoperative pain were evaluated in Japanese patients. The objective was to assess whether celecoxib showed superiority over placebo treatment and non-inferiority versus etodolac (another selective cyclooxygenase-2 inhibitor) that has been widely used for the management of acute pain. A multicenter, double-blind, randomized, parallel-group, controlled study was performed, in which 616 patients with postoperative pain received celecoxib, etodolac, or placebo. Their impressions of study drug efficacy (overall assessment) and pain intensity were evaluated. Based on each patient’s overall assessment of pain, the efficacy rate was 63.7% in the placebo group, 76.2% in the celecoxib group, and 68.0% in the etodolac group, with these results demonstrating superiority of celecoxib to placebo and noninferiority versus etodolac. The efficacy rate was significantly higher in the celecoxib group than in the etodolac group. There were no adverse events specific to celecoxib, and the safety of celecoxib was similar to that of placebo. Celecoxib was superior to etodolac for controlling acute postoperative pain.", "subitem_description_type": "Abstract"}]}, "item_9_identifier_60": {"attribute_name": "URI", "attribute_value_mlt": [{"subitem_identifier_type": "URI", "subitem_identifier_uri": "http://www.med.nagoya-u.ac.jp/medlib/nagoya_j_med_sci/7712.html"}, {"subitem_identifier_type": "HDL", "subitem_identifier_uri": "http://hdl.handle.net/2237/21261"}]}, "item_9_identifier_registration": {"attribute_name": "ID登録", "attribute_value_mlt": [{"subitem_identifier_reg_text": "10.18999/nagjms.77.1-2.81", "subitem_identifier_reg_type": "JaLC"}]}, "item_9_publisher_32": {"attribute_name": "出版者", "attribute_value_mlt": [{"subitem_publisher": "Nagoya University School of Medicine"}]}, "item_9_select_15": {"attribute_name": "著者版フラグ", "attribute_value_mlt": [{"subitem_select_item": "publisher"}]}, "item_9_source_id_7": {"attribute_name": "ISSN(print)", "attribute_value_mlt": [{"subitem_source_identifier": "0027-7622", "subitem_source_identifier_type": "ISSN"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "ISHIGURO, NAOKI"}], "nameIdentifiers": [{"nameIdentifier": "55997", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "HANAOKA, AKIO"}], "nameIdentifiers": [{"nameIdentifier": "55998", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "OKADA, TOSHIYUKI"}], "nameIdentifiers": [{"nameIdentifier": "55999", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "ITO, MASANORI"}], "nameIdentifiers": [{"nameIdentifier": "56000", "nameIdentifierScheme": "WEKO"}]}]}, "item_files": {"attribute_name": "ファイル情報", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2018-02-21"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "15_Ishiguro.pdf", "filesize": [{"value": "425.5 kB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_free", "mimetype": "application/pdf", "size": 425500.0, "url": {"label": "15_Ishiguro.pdf", "url": "https://nagoya.repo.nii.ac.jp/record/19155/files/15_Ishiguro.pdf"}, "version_id": "8d48fe97-f421-410f-a085-c8363daf7a24"}]}, "item_keyword": {"attribute_name": "キーワード", "attribute_value_mlt": [{"subitem_subject": "Celecoxib", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Clinical study", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Placebo", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Etodolac", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Postoperative pain", "subitem_subject_scheme": "Other"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "departmental bulletin paper", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "Efficacy and Safety of Celecoxib Compared with Placebo and Etodolac for Acute Postoperative Pain: A Multicenter, Double-Blind, Randomized, Parallel-Group, Controlled Trail", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "Efficacy and Safety of Celecoxib Compared with Placebo and Etodolac for Acute Postoperative Pain: A Multicenter, Double-Blind, Randomized, Parallel-Group, Controlled Trail"}]}, "item_type_id": "9", "owner": "1", "path": ["1674"], "permalink_uri": "https://doi.org/10.18999/nagjms.77.1-2.81", "pubdate": {"attribute_name": "公開日", "attribute_value": "2015-02-26"}, "publish_date": "2015-02-26", "publish_status": "0", "recid": "19155", "relation": {}, "relation_version_is_last": true, "title": ["Efficacy and Safety of Celecoxib Compared with Placebo and Etodolac for Acute Postoperative Pain: A Multicenter, Double-Blind, Randomized, Parallel-Group, Controlled Trail"], "weko_shared_id": null}
  1. C100 医学部/医学系研究科
  2. C100b 紀要
  3. Nagoya journal of medical science
  4. 77(1-2)

Efficacy and Safety of Celecoxib Compared with Placebo and Etodolac for Acute Postoperative Pain: A Multicenter, Double-Blind, Randomized, Parallel-Group, Controlled Trail

https://doi.org/10.18999/nagjms.77.1-2.81
https://doi.org/10.18999/nagjms.77.1-2.81
0d094fc4-44b4-4420-8771-fefe770bc511
名前 / ファイル ライセンス アクション
15_Ishiguro.pdf 15_Ishiguro.pdf (425.5 kB)
Item type 紀要論文 / Departmental Bulletin Paper(1)
公開日 2015-02-26
タイトル
タイトル Efficacy and Safety of Celecoxib Compared with Placebo and Etodolac for Acute Postoperative Pain: A Multicenter, Double-Blind, Randomized, Parallel-Group, Controlled Trail
著者 ISHIGURO, NAOKI

× ISHIGURO, NAOKI

WEKO 55997

ISHIGURO, NAOKI

Search repository
HANAOKA, AKIO

× HANAOKA, AKIO

WEKO 55998

HANAOKA, AKIO

Search repository
OKADA, TOSHIYUKI

× OKADA, TOSHIYUKI

WEKO 55999

OKADA, TOSHIYUKI

Search repository
ITO, MASANORI

× ITO, MASANORI

WEKO 56000

ITO, MASANORI

Search repository
キーワード
主題Scheme Other
主題 Celecoxib
キーワード
主題Scheme Other
主題 Clinical study
キーワード
主題Scheme Other
主題 Placebo
キーワード
主題Scheme Other
主題 Etodolac
キーワード
主題Scheme Other
主題 Postoperative pain
抄録
内容記述 Celecoxib is a nonsteroidal anti-inflammatory drug (selective cyclooxygenase-2 inhibitor) that is widely used. The efficacy and safety of celecoxib for treatment of acute postoperative pain were evaluated in Japanese patients. The objective was to assess whether celecoxib showed superiority over placebo treatment and non-inferiority versus etodolac (another selective cyclooxygenase-2 inhibitor) that has been widely used for the management of acute pain. A multicenter, double-blind, randomized, parallel-group, controlled study was performed, in which 616 patients with postoperative pain received celecoxib, etodolac, or placebo. Their impressions of study drug efficacy (overall assessment) and pain intensity were evaluated. Based on each patient’s overall assessment of pain, the efficacy rate was 63.7% in the placebo group, 76.2% in the celecoxib group, and 68.0% in the etodolac group, with these results demonstrating superiority of celecoxib to placebo and noninferiority versus etodolac. The efficacy rate was significantly higher in the celecoxib group than in the etodolac group. There were no adverse events specific to celecoxib, and the safety of celecoxib was similar to that of placebo. Celecoxib was superior to etodolac for controlling acute postoperative pain.
内容記述タイプ Abstract
出版者
出版者 Nagoya University School of Medicine
言語
言語 eng
資源タイプ
資源 http://purl.org/coar/resource_type/c_6501
タイプ departmental bulletin paper
ID登録
ID登録 10.18999/nagjms.77.1-2.81
ID登録タイプ JaLC
ISSN(print)
収録物識別子タイプ ISSN
収録物識別子 0027-7622
書誌情報 Nagoya Journal of Medical Science

巻 77, 号 1-2, p. 81-93, 発行日 2015-02
著者版フラグ
値 publisher
URI
識別子 http://www.med.nagoya-u.ac.jp/medlib/nagoya_j_med_sci/7712.html
識別子タイプ URI
URI
識別子 http://hdl.handle.net/2237/21261
識別子タイプ HDL
戻る
0
views
See details
Views

Versions

Ver.1 2021-03-01 16:20:48.036395
Show All versions

Share

Mendeley Twitter Facebook Print Addthis

Cite as

エクスポート

OAI-PMH
  • OAI-PMH JPCOAR
  • OAI-PMH DublinCore
  • OAI-PMH DDI
Other Formats
  • JSON
  • BIBTEX

Confirm


Powered by WEKO3


Powered by WEKO3